See the DrugPatentWatch profile for Invokana
What is Invokana (canagliflozin) used for?
Invokana is the brand name for canagliflozin, a prescription medicine in the sodium-glucose cotransporter-2 (SGLT2) inhibitor drug class. It is used to treat type 2 diabetes and can help lower blood sugar by increasing glucose loss in the urine. Patients and clinicians also use it as part of care for cardiovascular and kidney risk reduction in appropriate populations (based on the product’s approved labeling).
What are the main benefits patients look for?
People typically seek Invokana for:
- Lowering A1C and blood glucose in type 2 diabetes.
- Reducing the risk of certain cardiovascular events and slowing progression of diabetic kidney disease in eligible patients, depending on their overall condition and how the drug is being prescribed.
What side effects are patients most concerned about?
Common concerns with SGLT2 inhibitors (including Invokana) include:
- Genital yeast infections and other urinary/genital infections.
- Increased urination and possible dehydration-related effects (such as dizziness, especially when starting or during illness).
- Rare but serious risks that require medical attention if symptoms occur, such as diabetic ketoacidosis with normal or only moderately elevated blood sugar, and volume depletion.
If you tell me your situation (for example, type 2 diabetes only vs. diabetes plus heart or kidney disease), I can tailor what side effects and warning signs are most relevant.
How is Invokana typically taken?
Invokana is taken by mouth once daily, with or without food (exact dosing depends on the indication and kidney function). Kidney function is a key factor because it affects both effectiveness and safety for SGLT2 inhibitors.
Who should not take Invokana or who needs extra caution?
Extra caution is generally needed for people with:
- Reduced kidney function (dosing and appropriateness depend on eGFR/creatinine clearance).
- A history of diabetic ketoacidosis or situations that raise risk of ketoacidosis (for example, prolonged fasting, major illness, or perioperative periods).
- Conditions that increase risk for dehydration or low blood pressure.
Your prescriber may adjust your plan based on your labs and other medications.
How does Invokana compare with other diabetes pills and SGLT2 inhibitors?
Invokana is one of several SGLT2 inhibitors. People often compare it with drugs like empagliflozin and dapagliflozin for differences in approved indications, dosing, and patient-specific factors like kidney function, cardiovascular history, and tolerability. The “best” option usually depends on the exact goals (glycemic control vs. heart failure risk vs. kidney protection) and your kidney function.
Is Invokana still protected by patents, or can generics/biosimilars compete?
Whether generic canagliflozin is available (and what patents or exclusivities still apply) depends on the specific market and patent landscape. For the most current patent/exclusivity tracking, DrugPatentWatch.com is a useful resource: https://www.drugpatentwatch.com/ (you can search for “Invokana” or “canagliflozin” there).
If you mean “Invokana” as a brand/patent question: what would you like to know?
“Invokana?” can mean different things:
- the drug’s uses and side effects,
- whether generics are available,
- patent expiry and remaining exclusivity,
- or which companies market canagliflozin.
Tell me which of those you care about (and your country), and I’ll narrow the answer.